(VIANEWS) – Another day of trading has ended and here's today's list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are Molecular Data, ENDRA Life Sciences, and PAVmed.

The three most active and biggest losers today are Aurora Cannabis, Ironwood Investment Management, LLC, and Aurora Cannabis.

Most Active Winners today

1. Molecular Data (MKD) – 828.5%

Through its subsidiaries, Molecular Data Inc. operates in China's chemical ecommerce market. Through its integrated solutions, the company provides a technology-driven platform to connect participants across the entire chemical value chain. It delivers e-commerce solutions, financial solutions, warehousing and logistics solutions, and software-as-a-service suites that are intended to solve pain points for participants in the traditional chemical industry. It offers its online solutions via molbase.com, molbase.cn and Moku Data Weixin accounts; Chemical Community app; as well other platforms. Shanghai is the headquarters of this company, which was established in 2013.

NASDAQ ended the session with Molecular Data rising 828.5% to $0.94 on Monday, after two successive sessions in a row of losses. NASDAQ rose 3.33% to $12,131.13, after three successive sessions in a row of gains, on what was a very positive trend trading session today.

Volume

Today's last reported volume for Molecular Data is 728912 which is 44.67% below its average volume of 1317630.

Molecular Data's last close was $0.94, 94.06% under its 52-week high of $15.75.

Molecular Data's Revenue

Year-on-year quarterly revenue growth declined by 67.1%, now sitting on 4.62B for the twelve trailing months.

Molecular Data's Stock Yearly Top and Bottom Value

Molecular Data's stock is valued at $0.94 at 17:32 EST, way below its 52-week high of $15.75 and way higher than its 52-week low of $0.77.

Molecular Data's Moving Average

Molecular Data's worth is way below its 50-day moving average of $2.17 and way below its 200-day moving average of $3.74.

More news about Molecular Data.

2. ENDRA Life Sciences (NDRAW) – 150%

NASDAQ ended the session with ENDRA Life Sciences rising 150% to $0.03 on Monday while NASDAQ rose 3.33% to $12,131.13.

ENDRA Life Sciences's last close was $0.03, 0% under its 52-week high of $0.03.

ENDRA Life Sciences's Stock Yearly Top and Bottom Value

ENDRA Life Sciences's stock is valued at $0.03 at 17:32 EST, way below its 52-week low of $0.01.

More news about ENDRA Life Sciences.

3. PAVmed (PAVMW) – 105.67%

PAVmed Inc. is a United States-based medical device company. CarpX is a percutaneous device that treats carpal tunnel syndrome. EsoCheck (esophageal cell collection instrument for early detection of Barrett's Esophagus or adenocarcinoma) are the company's leading products. The company's products include EsoGuard (a molecular diagnostic DNA test for the esophageal); EsoCure (an esophageal ablation tool to treat dysplastic BE); NextFlo (a disposable infusion platform tech); PortIO (an implantable intraosseous access device); DisappEAR (a resorbable pediatric tube), NextCath, and Caldus. In April 2015, the company changed its name from PAXmed Inc. to PAVmed Inc. PAVmed Inc. was founded in 2014. It is located in New York, New York.

NASDAQ ended the session with PAVmed jumping 105.67% to $0.03 on Monday, following the last session's downward trend. NASDAQ jumped 3.33% to $12,131.13, after three consecutive sessions in a row of gains, on what was a very positive trend trading session today.

Volume

Today's last reported volume for PAVmed is 32626 which is 397.12% above its average volume of 6563.

PAVmed's last close was $0.03, 99.39% under its 52-week high of $4.74.

PAVmed's Stock Yearly Top and Bottom Value

PAVmed's stock is valued at $0.03 at 17:32 EST, way under its 52-week high of $4.74 and way above its 52-week low of $0.02.

PAVmed's Moving Average

PAVmed's value is way under its 50-day moving average of $0.21 and way under its 200-day moving average of $1.66.

More news about PAVmed.

4. Oncternal Therapeutics (ONCT) – 88.08%

Oncternal Therapeutics, Inc. is a biopharmaceutical company at the clinical stage. It focuses its efforts on developing oncology treatments for cancers that have a critical unmet medical demand. The company's pipeline also includes cirmtuzumab (an investigational monoclonal anti-inflammatory antibody) that is currently being tested in a Phase 1/2 clinical study in conjunction with ibrutinib to treat patients with B cell lymphoid malignancies such as mantle cells lymphoma or chronic lymphocytic Leukemia. A chimeric antigen receptor-like T cell therapy is being developed by the company. It targets Receptor Tyrosine Kinase-like Orphan Receptor 1. This treatment could be used to treat solid tumors as well as other hematologic diseases. It is also developing TK216 an investigational small molecule to inhibit the E26 Transformation Specific Family of oncoproteins. Oncternal Therapeutics, Inc. holds license agreements with Georgetown University, Shanghai Pharmaceutical (USA), Inc., Selexis S.A., and the University of Tennessee Research Foundation. San Diego is the company's headquarters.

NASDAQ ended the session with Oncternal Therapeutics rising 88.08% to $1.54 on Monday while NASDAQ jumped 3.33% to $12,131.13.

Volume

Today's last reported volume for Oncternal Therapeutics is 20994200 which is 3155.5% above its average volume of 644884.

Oncternal Therapeutics 's last close was $1.54, 73.81% below its 52-week high of $5.88.

Oncternal Therapeutics 's Sales

Oncternal Therapeutics 's sales growth is a negative 47.9% for the ongoing quarter and a decline by 62.3% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 43.8% and a negative 21.1%, respectively.

Oncternal Therapeutics 's Revenue

Year-on-year quarterly revenue growth declined by 0.3%, now sitting on 4.31M for the twelve trailing months.

Oncternal Therapeutics 's Stock Yearly Top and Bottom Value

Oncternal Therapeutics 's stock is valued at $1.54 at 17:32 EST, way under its 52-week high of $5.88 and way higher than its 52-week low of $0.69.

Oncternal Therapeutics 's Moving Average

Oncternal Therapeutics 's worth is way higher than its 50-day moving average of $1.11 and way under its 200-day moving average of $2.55.

More news about Oncternal Therapeutics .

5. National Energy Services Reunited Corp. (NESRW) – 56.18%

NASDAQ ended the session with National Energy Services Reunited Corp. rising 56.18% to $1.04 on Monday, after five sequential sessions in a row of losses. NASDAQ jumped 3.33% to $12,131.13, after three sequential sessions in a row of gains, on what was a very bullish trend trading session today.

National Energy Services Reunited Corp.'s last close was $1.04, 0% under its 52-week high of $1.04.

National Energy Services Reunited Corp.'s Stock Yearly Top and Bottom Value

National Energy Services Reunited Corp.'s stock is valued at $1.04 at 17:32 EST, under its 52-week low of $1.04.

More news about National Energy Services Reunited Corp..

6. Meten EdtechX Education Group Ltd. (METXW) – 41.51%

NASDAQ ended the session with Meten EdtechX Education Group Ltd. jumping 41.51% to $0.10 on Monday, after five sequential sessions in a row of losses. NASDAQ rose 3.33% to $12,131.13, after three successive sessions in a row of gains, on what was a very bullish trend exchanging session today.

Meten EdtechX Education Group Ltd.'s last close was $0.10, 2.36% under its 52-week high of $0.10.

Meten EdtechX Education Group Ltd.'s Stock Yearly Top and Bottom Value

Meten EdtechX Education Group Ltd.'s stock is valued at $0.10 at 17:32 EST, below its 52-week high of $0.10 and above its 52-week low of $0.09.

More news about Meten EdtechX Education Group Ltd..

7. Vmware (VMW) – 36.13%

VMware, Inc. offers software for hybrid cloud, multicloud, modern apps, security, networking, and digital workspaces both in the United States as well internationally. VMware vSphere is a platform that allows users to install hypervisor. This layer of software is located between the operating system's hardware and operates to allow compute virtualization. It also offers cloud management products to help businesses automate, programmable provision, and monitor their applications. Customers can also access networking products and services, as well as storage and availability products that include data storage options and protection. It also offers VMware Cloud Foundation. This platform combines compute, storage and networking technologies with cloud administration to create an integrated stack that delivers enterprise-ready cloud infrastructure in private and public clouds. It also offers hybrid cloud computing services, including VMware Cloud Foundation, VMware Cloud Provider Program and VMware Cloud Services. Workspace ONE delivers and manages all applications on every device. This includes pivotal cloud findry, pivotal labs and heptio as well as access control, multi-platform management and application management. It sells products via distributors, resellers and system vendors. VMware, Inc. is a strategic partner with Amazon Web Services, which will build and deliver an integrated solution. SNC-Lavalin, on the other hand, will provide a digital collaboration platform to facilitate project delivery. It was founded in 1998, and its headquarters are in Palo Alto (California). VMware, Inc., is a subsidiary Dell Technologies Inc.

NYSE ended the session with Vmware rising 36.13% to $129.26 on Monday while NYSE jumped 1.78% to $15,942.62.

Volume

Today's last reported volume for Vmware is 5826070 which is 194.03% above its average volume of 1981450.

Vmware's last close was $129.26, 22.98% under its 52-week high of $167.83.

The company's growth estimates for the present quarter and the next is a negative 10.8% and a negative 4%, respectively.

Vmware's Revenue

Year-on-year quarterly revenue growth grew by 7.2%, now sitting on 12.85B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Vmware's stock is considered to be oversold (<=20).

Vmware's Stock Yearly Top and Bottom Value

Vmware's stock is valued at $129.26 at 17:32 EST, way below its 52-week high of $167.83 and way above its 52-week low of $91.53.

Vmware's Moving Average

Vmware's value is way above its 50-day moving average of $109.28 and higher than its 200-day moving average of $127.43.

More news about Vmware.

8. Southwestern Energy (SWN) – 34.68%

Southwestern Energy Company is an independent energy company that specializes in exploration, development and production of natural and oil in the United States. The company operates in Exploration and Production and Marketing segments. It focuses its efforts on developing unconventional natural gas reserves in West Virginia and Pennsylvania. It had 173,994 acres of Northeast Appalachia and 287,693 acres in Southwest Appalachia as of December 31, 2019. Its proved oil and natural gas reserves, as well as NGLs and natural gas reserves, are estimated at 12,721 Bcfe. There is 929 Bcfe in undeveloped proven reserves. The company also markets natural gas, oil and NGLs. It provides services to energy companies and utilities as well as industrial buyers of natural gas. Southwestern Energy Company was established in 1929. It is located in Spring, Texas.

NYSE ended the session with Southwestern Energy jumping 34.68% to $9.32 on Monday while NYSE jumped 1.78% to $15,942.62.

Volume

Today's last reported volume for Southwestern Energy is 33228800 which is 5.33% below its average volume of 35101000.

Southwestern Energy's last close was $9.32, 7.37% above its 52-week high of $8.68.

Southwestern Energy's Sales

Southwestern Energy's sales growth is 44.2% for the present quarter and a decline by 3.4% for the next. The company's growth estimates for the current quarter and the next is 57.9% and 29.2%, respectively.

Southwestern Energy's Revenue

Year-on-year quarterly revenue growth grew by 174.5%, now sitting on 8.54B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Southwestern Energy's stock is considered to be oversold (<=20).

Southwestern Energy's Stock Yearly Top and Bottom Value

Southwestern Energy's stock is valued at $9.32 at 17:32 EST, higher than its 52-week high of $8.68.

Southwestern Energy's Moving Average

Southwestern Energy's worth is way above its 50-day moving average of $7.01 and way higher than its 200-day moving average of $5.39.

More news about Southwestern Energy.

9. Merus N.V. (MRUS) – 32.55%

Merus N.V. is a Dutch clinical-stage immunooncology company that focuses on the development and discovery of bispecific antibodies therapeutics. The company's bispecific antibody candidates pipeline also includes Zenocutuzumab, (MCLA-128) which is currently in a Phase 2 clinical trial to treat patients with metastatic breast carcinoma. It will also be available in Phase 1/2, for pancreatic, lung, and other solid tumours. The company also has MCLA-117, which is currently in phase 1 clinical trials for patients with acute myeloidleukemia. MCLA-158 is also in phase 1 clinical trials for treatment of solid tumours. ONO-4685 is a Phase I clinical trial to treat autoimmune diseases. MCLA-129 is being researched and developed by Betta Pharmaceuticals Co. Ltd. MCLA-145 is being created in collaboration and Incyte Corporation. Clinical programs are also being offered to examine potential combinations therapies and indications. Merus N.V. is a partner in research and development of novel bispecific T-cell-redirecting antibodies through a license agreement and collaborations with Loxo Oncology at Lilly. It was founded in Utrecht in the Netherlands in 2003.

NASDAQ ended the session with Merus N.V. jumping 32.55% to $18.53 on Monday while NASDAQ jumped 3.33% to $12,131.13.

Volume

Today's last reported volume for Merus N.V. is 675952 which is 186.29% above its average volume of 236107.

Merus N.V.'s last close was $18.53, 44% below its 52-week high of $33.09.

Merus N.V.'s Sales

Merus N.V.'s sales growth is a negative 15.6% for the ongoing quarter and a decline by 14.8% for the next. The company's growth estimates for the ongoing quarter is 14.1% and a drop 53.8% for the next.

Merus N.V.'s Revenue

Year-on-year quarterly revenue growth grew by 39.6%, now sitting on 52.41M for the twelve trailing months.

Merus N.V.'s Stock Yearly Top and Bottom Value

Merus N.V.'s stock is valued at $18.53 at 17:32 EST, way under its 52-week high of $33.09 and way higher than its 52-week low of $13.47.

Merus N.V.'s Moving Average

Merus N.V.'s value is way under its 50-day moving average of $22.09 and way under its 200-day moving average of $25.63.

More news about Merus N.V..

10. Antero Resources (AR) – 27.21%

Antero Resources Corporation is an independent oil-and-natural gas company that acquires, investigates, develops and produces natural gaz, natural gas liquids and other oil properties throughout the United States. The company owned approximately 451,000 acres of net land in the Marcellus Shale's southwestern core and 91,000 acres of net land in the Utica Shale core as of December 31, 2019. The company also operated 324 mile of Marcellus Shale gas gathering pipelines, 17 compressor stations and 110 miles of Utica Shale low-pressure/high-pressure gathering pipelines. It also owns and operates 8 miles high-pressure pipelines and two compressor stations. It had proved natural gas reserves estimated at 18.9 trillion cubic yards, which included 11.5 trillion cubic meters of natural gas, 652 million barrels assumed-recovered ethane and 540 million barrels each of normal butane and propane; as well as 42 million barrels oil. Antero Resources Appalachian Corporation was the company's former name. In June 2013, it changed its name from Antero Resources Corporation to Antero Resources Corporation. Antero Resources Corporation was established in 2002. It is located in Denver, Colorado.

NYSE ended the session with Antero Resources rising 27.21% to $44.74 on Monday while NYSE rose 1.78% to $15,942.62.

Volume

Today's last reported volume for Antero Resources is 6300230 which is 26.09% below its average volume of 8524230.

Antero Resources's last close was $44.74, 0.09% below its 52-week high of $44.78.

The company's growth estimates for the ongoing quarter and the next is 1007.7% and 689.5%, respectively.

Antero Resources's Revenue

Year-on-year quarterly revenue growth grew by 30.5%, now sitting on 6.93B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Antero Resources's stock is considered to be oversold (<=20).

Antero Resources's Stock Yearly Top and Bottom Value

Antero Resources's stock is valued at $44.74 at 17:32 EST, under its 52-week high of $44.78 and way above its 52-week low of $10.91.

Antero Resources's Moving Average

Antero Resources's worth is way higher than its 50-day moving average of $33.88 and way above its 200-day moving average of $22.63.

More news about Antero Resources.

Most Active Losers Today

1. Aurora Cannabis (ACB) – -44.74%

NYSE ended the session with Aurora Cannabis dropping 44.74% to $1.68 on Monday while NYSE jumped 1.78% to $15,942.62.

Volume

Today's last reported volume for Aurora Cannabis is 110527000 which is 1120.17% above its average volume of 9058310.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Aurora Cannabis's stock is considered to be overbought (>=80).

Previous days news about Aurora Cannabis

• Aurora cannabis upsizes bought deal financing. According to Benzinga on Friday, 27 May, "Why Should Investors Keep An Eye On Aurora Cannabis Stock Despite A Weak Quarter?"

More news about Aurora Cannabis.

2. Ironwood Investment Management, LLC (ACB) – -44.74%

NYSE ended the session with Ironwood Investment Management, LLC dropping 44.74% to $1.68 on Monday while NYSE rose 1.78% to $15,942.62.

Volume

Today's last reported volume for Ironwood Investment Management, LLC is 110527000 which is 1120.17% above its average volume of 9058310.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Ironwood Investment Management, LLC's stock is considered to be overbought (>=80).

More news about Ironwood Investment Management, LLC.

3. Aurora Cannabis (ACB) – -44.74%

NYSE ended the session with Aurora Cannabis falling 44.74% to $1.68 on Monday while NYSE rose 1.78% to $15,942.62.

Volume

Today's last reported volume for Aurora Cannabis is 110527000 which is 1120.17% above its average volume of 9058310.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Aurora Cannabis's stock is considered to be overbought (>=80).

Previous days news about Aurora Cannabis

• Aurora cannabis upsizes bought deal financing. According to Benzinga on Friday, 27 May, "Why Should Investors Keep An Eye On Aurora Cannabis Stock Despite A Weak Quarter?"

More news about Aurora Cannabis.

4. Ironwood Investment Management, LLC (ACB) – -44.74%

NYSE ended the session with Ironwood Investment Management, LLC sliding 44.74% to $1.68 on Monday while NYSE jumped 1.78% to $15,942.62.

Volume

Today's last reported volume for Ironwood Investment Management, LLC is 110527000 which is 1120.17% above its average volume of 9058310.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Ironwood Investment Management, LLC's stock is considered to be overbought (>=80).

More news about Ironwood Investment Management, LLC.

5. Snap (SNAP) – -32.84%

NYSE ended the session with Snap sliding 32.84% to $15.58 on Monday while NYSE rose 1.78% to $15,942.62.

Volume

Today's last reported volume for Snap is 66159100 which is 80.31% above its average volume of 36691800.

Snap's last close was $15.58, 81.31% under its 52-week high of $83.34.

The company's growth estimates for the present quarter and the next is a negative 80% and a negative 41.2%, respectively.

Snap's Revenue

Year-on-year quarterly revenue growth grew by 38.1%, now sitting on 4.41B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Snap's stock is considered to be oversold (<=20).

Snap's Stock Yearly Top and Bottom Value

Snap's stock is valued at $15.58 at 17:32 EST, way below its 52-week low of $20.95.

Snap's Moving Average

Snap's value is way below its 50-day moving average of $30.98 and way under its 200-day moving average of $48.94.

More news about Snap.

6. Liquidia Technologies (LQDA) – -29.58%

Liquidia Corporation is a biopharmaceutical firm that develops and manufactures products to meet unmet medical needs. LIQ861, an oral dry powder formulation treprostinil to treat pulmonary arterial hypertension, and LIQ865, which is a sustained-release formulation bupivacaine to relieve local pain after surgery are two of its product candidates. Generic treprostinil injection is also distributed by the company in the United States. Liquidia Corporation was established in 2004 in Morrisville in North Carolina.

NASDAQ ended the session with Liquidia Technologies dropping 29.58% to $4.07 on Monday, after three sequential sessions in a row of gains. NASDAQ jumped 3.33% to $12,131.13, after three sequential sessions in a row of gains, on what was a very bullish trend exchanging session today.

Volume

Today's last reported volume for Liquidia Technologies is 872023 which is 4.42% above its average volume of 835084.

Liquidia Technologies's last close was $4.07, 47.69% under its 52-week high of $7.78.

Liquidia Technologies's Sales

Liquidia Technologies's sales growth is 103.5% for the present quarter and 17.6% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 69.2% and a negative 71.4%, respectively.

Liquidia Technologies's Revenue

Year-on-year quarterly revenue growth grew by 13.2%, now sitting on 13.26M for the twelve trailing months.

Liquidia Technologies's Stock Yearly Top and Bottom Value

Liquidia Technologies's stock is valued at $4.07 at 17:32 EST, way under its 52-week high of $7.78 and way higher than its 52-week low of $2.25.

Liquidia Technologies's Moving Average

Liquidia Technologies's worth is way below its 50-day moving average of $5.91 and way under its 200-day moving average of $4.80.

More news about Liquidia Technologies.

7. NeuroMetrix (NURO) – -25.45%

NeuroMetrix, Inc., is a healthcare company that develops and markets products to detect, diagnose, and monitor peripheral nerve and spine cord disorders. It develops neuro-stimulation therapy devices for wear and points-of-care diagnostic tests for neuropathy to treat chronic conditions such as diabetes, chronic pain and sleep disorders. The company's most popular products are Quell which is a wearable device that provides relief from chronic, intractable, pain. This includes nerve pain caused by diabetes or lower back pain; DPNCheck, which can be used to diagnose systemic neuropathies such as diabetic peripheral nerve neuropathy. ADVANCE, an online platform, allows for traditional nerve conduction studies to be performed; and SENSUS. A pain therapy device that uses transcutaneous electrical nerve stimulation to relieve chronic, intractable, pain. It sells its products to customers, retailers, TV promotors, doctors, nurses, and other health professionals. The company operates across the United States and Mexico, as well as in Europe, Japan China, China, Middle East, Mexico, and China. GlaxoSmithKline has been a strategic partner of the company. NeuroMetrix, Inc., was established in 1996. It is located in Woburn, Massachusetts.

NASDAQ ended the session with NeuroMetrix sliding 25.45% to $4.10 on Monday while NASDAQ jumped 3.33% to $12,131.13.

Volume

Today's last reported volume for NeuroMetrix is 420499 which is 73.89% below its average volume of 1610720.

NeuroMetrix's last close was $4.10, 89.42% below its 52-week high of $38.75.

NeuroMetrix's Revenue

Year-on-year quarterly revenue growth grew by 6.8%, now sitting on 8.4M for the twelve trailing months.

NeuroMetrix's Stock Yearly Top and Bottom Value

NeuroMetrix's stock is valued at $4.10 at 17:32 EST, way below its 52-week high of $38.75 and way above its 52-week low of $2.70.

NeuroMetrix's Moving Average

NeuroMetrix's worth is above its 50-day moving average of $3.82 and way below its 200-day moving average of $6.44.

More news about NeuroMetrix.

8. Medigus Ltd. (MDGSW) – -22.93%

NASDAQ ended the session with Medigus Ltd. falling 22.93% to $0.24 on Monday, after five successive sessions in a row of losses. NASDAQ jumped 3.33% to $12,131.13, after three consecutive sessions in a row of gains, on what was a very bullish trend exchanging session today.

Medigus Ltd.'s last close was $0.24, 26.83% under its 52-week high of $0.33.

Medigus Ltd.'s Stock Yearly Top and Bottom Value

Medigus Ltd.'s stock is valued at $0.24 at 17:32 EST, way under its 52-week high of $0.33 and higher than its 52-week low of $0.22.

More news about Medigus Ltd..

9. NeuroBo Pharmaceuticals (NRBO) – -22.21%

NeuroBo Pharmaceuticals, Inc., is a biotechnology company in clinical stage that offers therapies for neurodegenerative, coronavirus, and other cardiometabolic disorders. Its therapeutics program includes ANA001, an oral niclosamide formulation that has been successfully tested in Phase 2 of a clinical trial for patients suffering from moderate coronavirus diseases (COVID-19); NB-01 to manage painful diabetic neuropathy and to modify neurodegenerative disease progressions associated with protein malfunctions; Gemcabene which is an acute indication of COVID-19. NeuroBo Pharmaceuticals, Inc., was established in 2017. It is located in Boston, Massachusetts.

NASDAQ ended the session with NeuroBo Pharmaceuticals falling 22.21% to $0.43 on Monday, following the last session's upward trend. NASDAQ rose 3.33% to $12,131.13, after three sequential sessions in a row of gains, on what was a very up trend exchanging session today.

Volume

Today's last reported volume for NeuroBo Pharmaceuticals is 94326 which is 53.33% below its average volume of 202128.

NeuroBo Pharmaceuticals's last close was $0.43, 93.44% under its 52-week high of $6.57.

NeuroBo Pharmaceuticals's Stock Yearly Top and Bottom Value

NeuroBo Pharmaceuticals's stock is valued at $0.43 at 17:32 EST, way under its 52-week high of $6.57 and way higher than its 52-week low of $0.38.

NeuroBo Pharmaceuticals's Moving Average

NeuroBo Pharmaceuticals's value is way below its 50-day moving average of $0.72 and way under its 200-day moving average of $1.65.

More news about NeuroBo Pharmaceuticals.

10. Canopy Growth (CGC) – -16.87%

NASDAQ ended the session with Canopy Growth sliding 16.87% to $4.88 on Monday, after three sequential sessions in a row of losses. NASDAQ rose 3.33% to $12,131.13, after three consecutive sessions in a row of gains, on what was a very up trend exchanging session today.

Volume

Today's last reported volume for Canopy Growth is 16635100 which is 124.69% above its average volume of 7403360.

Canopy Growth's last close was $4.88, 91.36% under its 52-week high of $56.50.

Canopy Growth's Revenue

Year-on-year quarterly revenue growth grew by 23.4%, now sitting on 572.44M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Canopy Growth's stock is considered to be overbought (>=80).

Canopy Growth's Stock Yearly Top and Bottom Value

Canopy Growth's stock is valued at $4.88 at 17:32 EST, way under its 52-week low of $9.54.

Canopy Growth's Moving Average

Canopy Growth's worth is way under its 50-day moving average of $12.63 and way below its 200-day moving average of $20.75.

Previous days news about Canopy Growth

• Canopy growth shares drop on wider-than-expected loss. According to MarketWatch on Friday, 27 May, "In FY2023, we are focused on executing our path to profitability in Canada, while we continue to invest in high potential opportunities — particularly in BioSteel, and further developing our U.S. THC ecosystem, which we believe remains significantly under-appreciated by the market." Prior to Friday's trades, shares of Canopy Growth are down 35.5% in 2022 compared to a drop of 25% by the Nasdaq and a loss of 41.9% by the Cannabis ETF .", "Looking ahead, Canopy Growth expects to generate positive adjusted Ebitda in fiscal year 2024, excluding investments in BioSteel drinks and its U.S. THC businesses. "
• Canopy growth stock earnings: CGC shares plummet on major earnings miss. According to FXStreet on Friday, 27 May, "This level may be months off as Canopy Growth will require some positivity around earnings in order to provoke any type of rally."

More news about Canopy Growth.

Stay up to date with our winners and losers daily report